Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2013 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Stifel Nicolaus Annual Healthcare Conference

TEL-AVIV, Israel, Sept. 3, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on...
August 20, 2013 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive European Regulatory Meetings Regarding Its European Phase III Plan for RHB-104 (Crohn's)

The Company recently held successful Scientific Advice Meetings with the UK and Swedish pharmaceutical regulatory agencies to discuss its European Phase III strategy with RHB-104 for Crohn's...
July 30, 2013 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results With RHB-104 and Plans for a Phase IIa Study

The planned phase IIa, proof of concept, clinical study will assess the efficacy and safety of RHB-104 in patients suffering from rheumatoid arthritis (RA) RA is one of the most common...
July 22, 2013 12:21 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Reports Results for the Second Quarter of 2013

RedHill continues advanced preparations for the Phase III study with RHB-104 (Crohn's) and Phase II/III study with RHB-105 (H. pylori) Key Highlights include: FDA acceptance of RHB-103...
July 11, 2013 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program

Following a Type B meeting with the FDA in February 2013, the Company commenced the first of two supplementary pharmacokinetic studies with RHB-102, with a second comparative bioavailability...
July 03, 2013 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the JMP Securities Annual Healthcare Conference in New York

TEL-AVIV, Israel, July 3, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the...
June 18, 2013 06:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces FDA Acceptance for Review of RHB-103 NDA for Acute Migraine and PDUFA Goal Date of February 3, 2014

The RHB-103 New Drug Application (NDA) for marketing approval in the U.S. is subject to a standard 10-month review period and will have a Prescription Drug User Fee Act (PDUFA) action date...
June 05, 2013 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Commences Patient Screening in a Phase IIa Clinical Trial With RHB-104 for Multiple Sclerosis

The open label Phase IIa study is designed to assess the efficacy and safety of RHB-104 in Multiple Sclerosis (MS) patients. The study follows successful completion of 4 pre-clinical...
May 29, 2013 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Positive FDA Meeting Regarding the Regulatory Path Towards NDA Submission of RHB-101 for the Treatment of Congestive Heart Failure and Hypertension

Following the prior successful completion of four pharmacokinetic (PK) clinical studies, the Company held a Type B meeting regarding RHB-101 with the U.S. Food and Drug Administration (FDA)...
May 28, 2013 09:02 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma to Present at the Jefferies 2013 Global Healthcare Conference in New York

TEL-AVIV, Israel, May 28, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the...